Eli Lilly and Company has been creating medicines that make life better for people worldwide for over 140 years. Founded in 1876, Lilly is committed to improving healthcare through innovation and research. Lilly focuses on three core values Integrity, Excellence, and Respect for People. These principles are a guide for the business in scientific discovery and patient care. To date, Eli continues to inspire and cater to the people.
Eli Lilly and Company Net Worth
Eli Lilly and Company is a global pharmaceutical company with a net worth of $823.05 billion. Over the years the company’s market cap has increased by 95.16% ranking it as the 10th among the company. The company has seen growth that makes it a master in the global pharmaceutical market.
Eli Lilly and Company & its profit & loss
Lilly is a leading pharmaceutical company with its robust pipeline and strategic acquisitions have helped with consistent growth and profits. The company for many years acquired assets that helped grow its sustenance tactics and liabilities that are a source to make profitable decisions.
Eli Lilly and Company Assets and Liabilities
Eli Lilly and Company is the largest pharmaceutical company headquartered in Indianapolis, USA. Founded in 1876 this company’s financial health is good and has total assets amounting to $63.94 billion. Over the past year, the market cap has increased by 94.34% its strong performance in the pharmaceutical and biotech sectors. Eli Lilly and Company’s total liabilities amount to $51.046 billion with a year-on-year increase of 21.92%. Its strong acquisitions and product pipeline have helped navigate industry challenges and kept the company in a safe financial position.
| Year | Total Assets | Total Liabilities | |
|---|---|---|---|
| 2023 | $64 billion | $53,143 | |
| 2022 | $49.48 billion | $38,714 | |
| 2021 | $48.80 billion | $39,651 | |
| 2020 | $46.63 billion | $40,808 | |
| 2019 | $39.28 billion | $36,587 | |
| 2018 | $43.90 billion | $32,999 | |
| 2017 | $44.98 billion | $33,313 | |
| 2016 | $38.80 billion | $24,725 |
Eli Lilly and Company stock market year over year
Lilly has seen substantial growth over the past decade with a robust performance. The average stock price stands at $632.09. Over the years keeping in mind its stock performance the company has still maintained its position as a leading pharmaceutical company.
| Year | Average Stock Price | Year Over Year % | Current Business | Current Valuation |
| 2024 | $740.85 | 49.03% | Consumer, banking and life insurance sectors | $866 |
| 2023 | $461.35 | 60.91% | Oil and gas, retail | $581 |
| 2022 | $301.79 | 34.24% | Fracking and retail | $361.06 |
| 2021 | $217.37 | 66.08% | Retail and energy | $268.97 |
| 2020 | $141.37 | 31.06% | Consumer finance and energy | $161.96 |
| 2019 | $108.77 | 15.48% | Insurance and consumer banking | $123.57 |
| 2018 | $85.70 | 40.45% | Hedge funds and international funds | $107.01 |
| 2017 | $73.26 | 17.83% | Private equity and international investments | $76.19 |
Eli Lilly and Company’s new acquisitions & its business
The company has made 24 acquisitions with a notable focus on biopharmaceuticals in life sciences in the US and Tech in the US. The collective cost of the acquisitions is $25 billion with its portfolio in areas such as neuroscience, oncology, and diabetes. Recent notable acquisitions include POINT Biopharma, Versanis Bio and Mablink.
Eli Lilly and Company comparison with competitors
Lilly operates in the competitive industry with several large pharmaceutical companies that include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY). It also competes with companies like Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Corcept Therapeutics (CORT). These competitors are spread across sectors like therapy, drug manufacturing and market share.
| COMPANY NAME | NET WORTH | FOUNDED YEAR | FOUNDER |
|---|---|---|---|
| Johnson & Johnson (JNJ) | $350.27 billion | 1886 | James, Edward Mead and Robert Johnson |
| Merck & Co., Inc. (MRK) | $327.95 billion | 1668 | Georg(e) Merck |
| AbbVie (ABBV) | $294.12 billion | 2013 | Richard A. Gonzalez |
| Pfizer (PFE) | $92.55 billion | 1966 | Charles Pfizer and Charles Erhart |
| Bristol-Myers Squibb (BMY) | $83.52 billion | 1887 | Chris Boerner |
| Zoetis (ZTS) | $77.82 billion | 1952 | Kristin Peck |
| Royalty Pharma (RPRX) | $12.41 billion | 1996 | Pablo Legorreta |
| Jazz Pharmaceuticals (JAZZ) | $7.12 billion | 2003 | Bruce C Cozadd |
Frequently Asked Questions
How is Eli Lilly and the company’s net worth calculated?
Lilly’s net worth is calculated based on its market capitalisation and total market valuation. Its shares and stock price help calculate the company’s net worth.
What factors have contributed to the year-on-year growth?
Several factors contribute to the year-on-year net worth growth of the company. The aspects include sales, acquisitions, shares and investments.
What are the recent developments that helped with the company’s net worth?
The company’s expansion into the launch of new drugs, new therapeutic areas and financial performance plays a crucial role.
Has the company’s net worth increased in recent years?
Yes, its strategic moves in the pharmaceutical sector have helped its net worth see a notable increase in recent years.
No schema found.
